NICE Urges Annual NHS Checks for 1-in-8 Women With PMOS

3 articles · Updated · bbc.co.uk · Jun 30

Draft NICE guidance says women with PMOS should get annual NHS reviews to speed diagnosis and monitor risks beyond core symptoms, including diabetes and heart disease.
Around 3 million to 4 million women in the UK have the condition, but NICE says it remains under-diagnosed and inconsistently managed despite being a major cause of female infertility.
The draft also tells clinicians when to suspect and diagnose PMOS, says it should not be ruled out after menopause, and notes higher prevalence in Black, Asian and mixed-ethnicity women.
Mental health, weight, diet, sleep and pregnancy planning are included in the recommended care, while laser and light hair-reduction therapies are not advised because of cost.
PMOS was renamed from polycystic ovary syndrome in May, and NICE will take consultation feedback until Aug. 11 before publishing final guidance in December 2026.

Sources

bbc.co.uk6h ago

NICE Draft Guidance Recommends Annual NHS Checks for Women with PMOS

AOL UK6h ago

Women with irregular periods should be checked for PMOS, NHS says - AOL

The Independent6h ago

PCOS and PMOS: The 'common but overlooked' condition that millions of women will now be reviewed for | The Independent

7 Sources

NICE advises annual PMOS checks. Can the strained NHS deliver this promise to four million women in the UK?

The name PCOS is gone. Will a new name truly change how doctors treat millions of women with PMOS?

If PMOS is now taken seriously, why is a key symptom treatment still considered too costly for the NHS?

From PCOS to PMOS: UK’s 2026 Guidelines Signal Major Overhaul in Diagnosis and Management for Millions

Overview

The UK's National Institute for Health and Care Excellence (NICE) has introduced a new draft guideline for Polyendocrine Metabolic Ovarian Syndrome (PMOS), launching a public consultation from July 1 to August 11, 2026. This process invites feedback from healthcare professionals, patients, and the public, with the final guideline expected in December 2026. A key recommendation is that laser hair removal and similar therapies should not be offered for hirsutism due to a lack of clinical evidence and uncertain cost-effectiveness. These steps aim to ensure that NHS resources are used for treatments proven to be effective and efficient.

...